Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Breast 1

Conditions

Stomach Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Psychiatric Rehabilitation 8Magnetic Resonance Spectroscopy 7Gemcitabine 7Capecitabine 7pembrolizumab 6Early Intervention, Educational 6Drug Therapy 6Cyclophosphamide 6Methods 5Therapeutics 4Specimen Handling 4Mental Status and Dementia Tests 4Docetaxel 4veliparib 3selpercatinib 3sargramostim 3palbociclib 3cediranib 3Trastuzumab 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Paclitaxel 3Oxaliplatin 3Irinotecan 3Fluorodeoxyglucose F18 3Counseling 3Cisplatin 3Carboplatin 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × devimistat × Breast × Clear all
NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Cornerstone Pharmaceuticals

Phase 2 Terminated
7 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡